August 13, 2019 04:15 AM EDT

Questions pile up for Novartis as senators call on FDA to take action

Zachary Brennan

Senior Editor

Why wait three months to tell the FDA about manipulated data? Why wait two months between documenting an initial issue and opening a nonconformance report …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER

Questions pile up for Novartis as senators call on FDA to take action

Zachary Brennan

Senior Editor

Sign up to read this article for free.

Sr. Manager/Associate Director, Document Control

Viridian Therapeutics

Waltham, MA, USA

Merck pays $30M to buy ‘chameleon’ approach to deadly brain cancers

Eye drop maker to merge with a retinal gene therapy startup from Spark co-founder

UK’s price watchdog says Lilly’s Alzheimer’s drug is too costly for broad uptake

Corrected: Sangamo to seek accelerated approval for Fabry gene therapy, claims it won't need confirmatory study

Amgen preps to launch Eylea biosimilar years early after Regeneron loses appeal

IDEAYA Biosciences: Targeting unmet market needs with precision oncology

Ques­tions pile up for No­var­tis as sen­a­tors call on FDA to take ac­tion

Senior Editor

Sign up to read this article for free.

Viridian Therapeutics

Waltham, MA, USA

Questions pile up for Novartis as senators call on FDA to take action